Back to Journals » Drug Design, Development and Therapy » Volume 4

A Phase I study of an intravesically administered immunotoxin targeting EpCAM for the treatment of nonmuscle-invasive bladder cancer in BCG-refractory and BCG-intolerant patients

Total article views   HTML views PDF downloads Totals
18,899 Dovepress* 17,078+ 2,068 19,146
PubMed Central* 1,821 670 2,491
Totals 18,899 2,738 21,637
*Since 15 November 2010
+Since July 2016
Total mentioned Facebook Delicious Reddit Twitter Others
8 0 0 0 0 8

View citations on PubMed Central and Google Scholar